Acrivon plans to initiate fourth cohort in ACR-368 Phase 2b study

Building on clinical data and observed biomarker upregulation in serous EC, the company announced today that it plans to initiate a fourth cohort in the ongoing ACR-368 Phase 2b study in the first half of 2026. This arm will enroll all-comer serous EC subjects, similar to Arm 3, but subjects will be treated with ACR-368 monotherapy and otherwise identical inclusion criteria to Arm 3. Company also announced today that it has completed the exploratory Arm 2 of the study which treated BM- EC subjects with less than or equal to3 prior LoT using ACR-368 with ULDG sensitization. Objectives of this arm were achieved, supporting that ULDG may contribute to ACR-368 efficacy in BM- subjects with a favorable tolerability profile.